![]() Heterozygous Pathogenic/Likely pathogenic germline variants in RAD50 and NBN are not clearly associated with an increased risk for cancer however, such variants may qualify certain patients for clinical trials targeting homologous recombination deficient tumors. Identification of a disease-causing variant would also guide testing and diagnosis of at-risk relatives. Genetic testing of these genes may confirm a diagnosis and help guide treatment and management decisions. The Invitae Multi-Cancer Panel is designed to maximize diagnostic yield for individuals with a personal or family history of mixed cancers affecting multiple organ systems. hematologic (myelodysplastic syndrome/leukemia).genitourinary (renal/urinary tract, prostate).endocrine (thyroid, paraganglioma/pheochromocytoma, parathyroid, pituitary). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |